ZNF724P Blocking Peptide
- Known as:
- ZNF724P Blocking Peptide
- Catalog number:
- 33r-4409
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Fitzgerald industries international
- Gene target:
- ZNF724P Blocking Peptide
Related genes to: ZNF724P Blocking Peptide
- Gene:
- ZNF724 NIH gene
- Name:
- zinc finger protein 724
- Previous symbol:
- ZNF724P
- Synonyms:
- -
- Chromosome:
- 19p12
- Locus Type:
- gene with protein product
- Date approved:
- 2006-06-30
- Date modifiied:
- 2017-11-24
Related products to: ZNF724P Blocking Peptide
Related articles to: ZNF724P Blocking Peptide
- The purpose of this study was to compare the transcriptomes of poorly cohesive carcinoma (PCC; diffuse-type) and well-differentiated tubular adenocarcinoma (WD; intestinal-type) using gastric cancer (GC) tissues and cell lines and to evaluate the prognostic role of HIV-1 Tat Interactive Protein 2 (HTATIP2). We performed next-generation sequencing with 8 GC surgical samples (5 WD and 3 PCC) and 3 GC cell lines (1 WD: MKN74, and 2 PCC: KATOIII and SNU601). Immunohistochemistry was used to validate HTATIP2 expression. We performed functional analysis by HTATIP2 overexpression (OE). Kaplan-Meier survival plots and the PrognoScan database were used for survival analysis. The genes with significantly reduced expression in PCC versus WD (in both tissues and cell lines) were HTATIP2, ESRP1, GRHL2, ARHGEF16, CKAP2L, and ZNF724. According to immunohistochemical staining, the HTATIP2-OE group had significantly higher number of patients with early GC (EGC) (T1) ( = .024), less lymph node (LN) metastasis ( = .008), and low TNMA stage ( = .017) than HTATIP2 underexpression (UE) group. Better survival rates were confirmed in the HTATIP2 OE group by Kaplan-Meir survival and PrognoScan analysis. In vitro, HTATIP2-OE in KATO III cells caused a significant decrease in cancer cell migration and invasion. Decreased Snail and Slug expression in HTATIP2 OE cells suggested that epithelial-mesenchymal transition is involved in this process. HTATIP2 might be a good prognostic marker and a candidate target for GC treatment. - Source: PubMed
Park Sun YiPark Ji-HoYang Jung WookJung Eun-JungJu Young-TaeJeong Chi-YoungKim Ju-YeonPark TaejinPark MiyeongLee Young-JoonJeong Sang-Ho - The first ever genome-wide association study (GWAS) of clinically defined gout cases and asymptomatic hyperuricaemia (AHUA) controls was performed to identify novel gout loci that aggravate AHUA into gout. - Source: PubMed
Publication date: 2019/07/08
Kawamura YusukeNakaoka HirofumiNakayama AkiyoshiOkada YukinoriYamamoto KenHigashino ToshihideSakiyama MasayukiShimizu ToruOoyama HiroshiOoyama KeikoNagase MitsuoHidaka YujiShirahama YukoHosomichi KazuyoshiNishida YuichiroShimoshikiryo IppeiHishida AsahiKatsuura-Kamano SakurakoShimizu SeikoKawaguchi MakotoUemura HirokazuIbusuki RieHara MegumiNaito MarikoTakao MikiyaNakajima MayukoIwasawa SatokoNakashima HiroshiOhnaka KeizoNakamura TakahiroStiburkova BlankaMerriman Tony RNakatochi MasahiroIchihara SahokoYokota MitsuhiroTakada TappeiSaitoh TatsuyaKamatani YoichiroTakahashi AtsushiArisawa KokichiTakezaki ToshiroTanaka KeitaroWakai KenjiKubo MichiakiHosoya TatsuoIchida KimiyoshiInoue IturoShinomiya NariyoshiMatsuo Hirotaka